Toboroz
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
NCT07388524· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Kevin M. Sullivan (principal investigator)
Toboroz
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
NCT07215910· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Samuel Singer (principal investigator)
Meghívásos bevonás
Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
NCT06773936· 2. fázis· SWOG Cancer Research Network· Forrás
Toboroz
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
NCT07166406· 3. fázis· NRG Oncology· Forrás
Contact: Baho U. Sidiqi (principal investigator)
Toboroz
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
NCT07198074· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Veena S. John (principal investigator)
Toboroz
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
NCT06686771· 3. fázis· Canadian Cancer Trials Group· Forrás
Contact: A. G. Wernicke (principal investigator)
Toboroz
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
NCT07061977· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Joan R. Tymon-Rosario (principal investigator)
Toboroz
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
NCT06992427· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Bhupesh Parashar (principal investigator)
Toboroz
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
NCT06661720· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Xinhua Zhu (principal investigator)
Fut, nem toboroz
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NCT06500455· 3. fázis· NRG Oncology· Forrás
Toboroz
Adjuvant Tebentafusp in High Risk Ocular Melanoma
NCT06246149· 3. fázis· European Organisation for Research and Treatment of Cancer - EORTC· Forrás
Contact: EORTC HQ
Toboroz
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
NCT06317649· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Erin Jou (principal investigator)
Toboroz
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
NCT05554406· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: David Chitty (principal investigator)
Toboroz
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
NCT06422806· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Tony Philip (principal investigator)
Toboroz
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
NCT06203600· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Crystal Antoine-Pepeljugoski (principal investigator)
Toboroz
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
NCT05564390· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: David Chitty (principal investigator)
Toboroz
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
NCT06235697· 3. fázis· Canadian Cancer Trials Group· Forrás
Contact: Sang E. Sim (principal investigator)
Fut, nem toboroz
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
NCT05863351· 3. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Toboroz
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NCT05946213· 3. fázis· NRG Oncology· Forrás
Contact: Janna Z. Andrews (principal investigator)
Toboroz
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
NCT06073431· University of Rochester· Forrás
Contact: Vincent P. Vinciguerra (principal investigator)
Toboroz
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926· 3. fázis· NRG Oncology· Forrás
Contact: Brittney S. Zimmerman (principal investigator)
Toboroz
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
NCT05673148· 2. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Sepideh Gholami (principal investigator)
Toboroz
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT05929768· 3. fázis· SWOG Cancer Research Network· Forrás
Contact: Brittney S. Zimmerman (principal investigator)
Toboroz
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
NCT05624996· 3. fázis· NRG Oncology· Forrás
Contact: Rajiv Sharma (principal investigator)
Toboroz
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT05812807· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Brittney S. Zimmerman (principal investigator)
Fut, nem toboroz
Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia
NCT05303792· 2. fázis· Alliance for Clinical Trials in Oncology· Forrás
Toboroz
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
NCT05327686· 2. fázis· NRG Oncology· Forrás
Contact: Clary Evans (principal investigator)
Toboroz
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
NCT05677490· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Tony Philip (principal investigator)
Fut, nem toboroz
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response
NCT05610163· 2/3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Toboroz
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
NCT05136196· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative
NCT04929041· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
NCT05111574· 2. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
NCT05174169· 2/3. fázis· NRG Oncology· Forrás
Contact: Craig E. Devoe (principal investigator)
Fut, nem toboroz
Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
NCT04637594· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Fut, nem toboroz
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
NCT05095376· 3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer
NCT04751370· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NCT05050084· 3. fázis· NRG Oncology· Forrás
Toboroz
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
NCT04858334· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Daniel A. King (principal investigator)
Fut, nem toboroz
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
NCT04739800· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
NCT04804644· 3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
NCT04647916· 2. fázis· SWOG Cancer Research Network· Forrás
Fut, nem toboroz
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
NCT04609046· 1. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
NCT04510597· 3. fázis· SWOG Cancer Research Network· Forrás
Contact: Thomas P. Bradley (principal investigator)
Fut, nem toboroz
Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer
NCT04559139· 2/3. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Fut, nem toboroz
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NCT04513717· 3. fázis· NRG Oncology· Forrás
Toboroz
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
NCT04031677· 3. fázis· European Organisation for Research and Treatment of Cancer - EORTC· Forrás
Contact: EORTC HQ
Fut, nem toboroz
Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma
NCT04339738· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
NCT04340141· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Toboroz
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
NCT04423211· 3. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Contact: Clary Evans (principal investigator)
Toboroz
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
NCT04333537· 2/3. fázis· NRG Oncology· Forrás
Showing 50 of 101.